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Abstract 
 
Background. Repair of skeletal muscle loss due to trauma, surgical resection or 
malformations represent a challenge for clinicians. Several attempts to create a 
bioscaffold to substitute skeletal muscle have been done but no satisfying results were 
obtained due to lack in regeneration process and functionality of repaired tissue. Some 
studies on tissue engineering investigated the application of decellularized extracellular 
matrix (ECM) derived from skeletal muscle observing positive effect towards 
regeneration. It is becoming relevant the role of tissue-specificity in the field of tissue 
engineering. This study aims to compare the regenerative effect of both tissue-specific 
and no tissue-specific scaffolds when applied in a volume of volume muscle loss. Muscle 
regeneration and macrophagic response are investigated. 
Material and Methods. Decellularized extracellular scaffold from murine skin, intestine 
and rhabdomyosarcoma (ARMS) were obtained using a detergent-enzymatic protocol. 
Scaffolds’ characteristics were investigated. Wild type mice were used as animal model 
for in vivo implantation on diaphragm and tibialis anterioris muscles. Samples were 
obtained at sequential timepoints and analysed with Histology, DNA quantification 
techniques, Immunofluorescence, Real-time PCR. 
Results. Decellularized ECM scaffold were obtained from each tissue. Moreover, their 
ECM maintained ultrastructure and composition. Implantation in vivo showed a 
regeneration of new, centre nucleated myofibers when muscle scaffold was used. No 
significant regeneration was observed with other scaffolds. With muscle implants, 
macrophagic response was present and characterized by organized distribution of cells.  
Conclusions. The decellularization protocol used in this study demonstrated to be 
effective in maintaining ECM properties even if in absence of cells. Pro-regenerative 
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results obtained only with implantation of muscle-derived scaffolds underline the 
importance of tissue-specificity in order to obtain the ideal material to repair muscular 
defects.  
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Introduction 
 
Skeletal muscle is one of the most represented tissue in human body, it is a contractile 
tissue that allows movements through tendons attached to the bones.  
Skeletal muscle injuries and defects have different origins. Congenital malformations, 
degenerative conditions, traumas and extended surgical resections may lead to a 
significant loss of muscle mass and functionality, when the loss is more than 20% is 
termed volumetric muscle loss (VML).  
In VML the innate regenerative potential of the muscle, efficient in repairing small 
wounds, is loss and mechanisms leading to regeneration are limited giving rise to an 
hypotrophic muscle with impaired functionality. 
The current standard of care for VML is autologous replacement transferring muscle 
tissue from a donor site of the same patient. In other cases, such as in congenital 
malformations with absent muscle portion, the defect is repaired using prosthetic patches 
of different materials. In all cases there is always a loss in muscle strength and 
functionality due to scar formation and lack in regeneration of real contractile tissue. 
Tissue engineering is a new frontier in treatment of skeletal muscle diseases. It aims to 
stimulate regeneration of muscle tissue to reach volume, structure and functionality close 
to the original condition.  
 
Skeletal muscle Anatomy 
 
A whole skeletal muscle is composed by hierarchical composition of elements which are 
coordinated during contraction. Contracting cells composing muscles are the myofibrils. 
The contractile unit of myofibrils is the sarcomere which consists of interposing filaments 
of actin and myosin A group of myofibrils form the so called myofibers that is the 
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structural basis of muscle. Similarly, myofibers forms a larger bundle inside the muscle 
called fascicles. At extremities skeletal muscle prolongates towards strong connective 
tissue forming tendons. These represents the connection between contractile tissue and 
the skeleton segments.  
Skeleton muscle is not only formed by contractile cells and structure, indeed inside 
muscle mass there are several components fundamental to its functionality and 
maintenance such as blood vessels and nerves that form a complex and extended network 
between subunits of muscle allowing adequate perfusion and regulating contraction 
respectively.  
An important role in muscle anatomy is also played by non-cellular elements. Each 
myofiber is surrounded by a basement membrane called basal lamina that is composed 
by fibronectin, type IV collagen, laminin and other proteins. Basal lamina acts as 
fundamental guide in the mechanism of endogenous tissue regeneration. Extracellular 
matrix (ECM) is the structure surrounding myofibers and it plays an important role in 
maintaining integrity of muscle and giving fundamental stimuli during reparative and 
regenerative processes. ECM is composed by several molecules of which most important 
are glycosaminoglycans, proteoglycans, collagen, fibronectin, lamin. 
Finally, between myofibers and basal lamina muscle stem cells are present, the so called 
satellite cells (SC). In healthy and mature muscle they are quiescent and they are the 
primary cell type responsible of muscle regeneration in case of damage. 
 
Muscle Regeneration 
 
Basis of muscle regeneration are similar to those of muscle development. Muscle 
development program is reactivated towards reconsruction when a tissue injury or volume 
loss occurs [1]. Satellite cells are committed toward regeneration, from the quiescent 
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satellite cells to the more fully differentiated muscle cells as shown in fig. 1. Satellite cells 
reside between the basal lamina and sarcolemma forming niches and remaining quiescent 
until their recruitment for formation and reparation of myofibers [8, 9]. Satellite cells can 
be activated both by physiological stimuli (such as exercise) or muscular damage. They 
express Pax7 transcription factor which induce the expression of others transcription 
factors (MyoD, Myf5, Myogenin, and MRF4) involved in the myogenic program. The 
activation of MyoD and Myf5 is fundamental for the formation of mature muscle cells 
[2].  
 
 
 
Fig. 1. From A Musarò. The Basis of Muscle Regeneration. Advances in Biology. Volume 2014. 
Article ID 612471. 
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Regeneration process after a muscular injury consists of different phases strictly inter-
related. These phases can be resumed in degeneration, inflammation, regeneration, 
remodelling and maturation (fig. 2). 
Degeneration. Necrosis of damaged myofibers produces debris and degradation elements 
which stimulate an inflammatory response. Inflammation plays a fundamental role in the 
equilibrium of the whole regenerative process and specific myeloid cells are recruited [3]. 
Neutrophils are the first cells to reach the damage site and they are detectable during first 
24 hours. They have a phagocytic activity during which pro-inflammatory cytokines and 
free radicals and protease are secreted [3, 4]. These molecules stimulate the homing of 
monocytes and macrophages at the site of injury. Macrophages are the most represented 
inflammatory cells and they can be found at the level of perimysium and epimysium. 
Their role is to eliminate the debris and to activate stem cells towards differentiation and 
maturation [5, 6]. There are two types of macrophages. Type 1 inflammatory 
macrophages (M1) are present during phases of phagocytosis and debris elimination. 
After that they switch into type 2 anti-inflammatory macrophages that are fundamental 
for the maintenance of an adequate environment for regeneration (M2) [5, 7]. 
Satellite cells play a key-role as stem cells in the phase of regeneration. After activation, 
they form myoblasts that will fuse with damaged myofibers or will generate new real 
myofibers. A small part of activated satellite cells remains undifferentiated and, after 
proliferation, re-enter quiescent phase to maintain the pool [10]. Myf5 is detectable in 
proliferating cells not committed to differentiation. Depending on MyoD expression 
proliferating cells may follow two different lines. Cells expressing MyoD downregulate 
Pax7 and activate myogenin expression towards differentiation. On contrary, the 
downregulation of MyoD drives the proliferating cells into the self-renewal cycle to 
maintain the stem cells pool [11, 12, 13].  
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Other non-muscle cells have been demonstrated to participate in regeneration. 
Endothelial associated cells, interstitial cells and bone marrow-derived cells involved in 
regenerative process can reside among myofibers or they can be recruited from 
bloodstream via homing signals. [14, 15, 16, 17]. 
There are specific interstitial cells, called fibro-adipocyte progenitor (FAP), which are 
quiescent while in contact with intact myofibers. After injuries in physiologic conditions 
they participate in muscle repair through paracrine factors and satellite cells-mediated 
regeneration. On the contrary, in degenerative disease or in extensive tissutal disruption, 
they turn into fibro-adipocyte committed to fat and fibrosis deposition responsible of 
muscle dystrophy [18, 19].  
Remodelling. Last phases of regeneration is remodelling of connective tissue with 
angiogenesis, and innervation to obtain the definitive maturation and functional repair. A 
key role during these phases is played by extracellular matrix. Regenerating tissue is 
stabilized by the production of structural molecules such as proteoglycans, collagen, 
fibronectin, elastin, laminin which re-organize into a scaffold driving the correct 
disposition of new myofibers, blood vessels and nerves [20]. Normal functionality of 
regenerated muscle is strictly dependent on innervation and this is especially relevant 
during last steps of regeneration. Indeed, within two weeks of damage new neuro-
muscular junctions can be identified and their activity can influence proliferating and 
maturating myofibers and their production of new myotubes. Satellite cells activity in 
regeneration has also been showed to be influenced by nerves activity [21, 22]. 
Extracellular matrix and its fundamental role in regeneration process and angiogenesis 
represent the main topic of this thesis and it will be widely discussed.  
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Fig. 2. Summary of different phases of regeneration process.  From A Musarò. The Basis of Muscle 
Regeneration. Advances in Biology. Volume 2014. Article ID 612471. 
 
 
Extracellular matrix 
 
Extracellular matrix (ECM) is a complex structure surrounding and supporting cells 
forming a tissue (Fig. 3). It has a three-dimensional architecture and it is composed by 
different molecules among which most relevant are glycosaminoglycans (GAGs), 
glycoproteins, collagen, elastin, laminin and fibronectin. Disposition of these molecules 
varies among different tissues implicating that ECM structure is specific and different 
among tissues and organs [23, 24].  
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Fig. 3. Schematic representation of extracellular matrix and interactions with cells. 
 
Collagen is present in the whole body as 20 or more subtypes but the most represented is 
Type I which is especially implicated in tendinous and ligamentous structure. Other 
frequent types of Collagen are Type III, IV, VI, and VII and they all provide structural 
strength [23]. Collagen arranges with glycoproteins, laminin and fibronectin into three-
dimensional structures. Fibronectin is another ECM component widely represented and 
it plays an adhesion role connecting to integrins on cellular surface. Laminin plays a role 
similar to fibronectin but it is also essential for formation and maintenance of vascular 
structures. GAG’s type mostly detectable are chondroitin sulfate A and B, heparin, and 
heparan sulfate. They are responsible for water retention and gel function of ECM. They 
also bind growth factors and cytokine. [23] 
Bioactive soluble cytokines and growth factors among structural molecules are 
fundamental for the modulation o cell behaviour. The most represented are fibroblast 
growth factor (FGF), epithelial growth factor, transforming growth factor beta (TGF-
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beta), keratinocyte growth factors, hepatocyte growth factor (HGF), platelet derived 
growth factor (PDGF), and vascular endothelial growth factor (VEGF) [23].  
Composition of many of the molecules described above is conserved through different 
species so that xenogenic ECM can be used for regenerative purpose avoiding the risk of 
rejection by the host. To be underlined is the different spatial and architectural disposition 
of molecules in ECM of different tissues. Even if components are similar, disposition and 
architecture are defined for each tissue. This aspect is fundamental when a regenerative 
purpose is intended. Indeed, architecture drives cells behaviour that can be different 
among tissues [24, 25, 26].  Moreover, architecture is the base of mechanical properties 
of the tissue, such as stiffness that has been shown to influence cell fate during 
differentiation [27, 28].  
ECM is a dynamic structure that can influence proliferation, survival, migration and 
differentiation of cells. It is always under constant remodelling and this is much important 
for development but also regeneration and repair of a tissue such as muscle [30]. There 
are several receptors having a role in signalling during ECM remodelling such as 
integrins, Laminin receptors, syndecans. Several modifying enzymes are involved in the 
process of remodelling. Metalloproteinases with other protease dissolve ECM molecules 
through their proteolytic activity. Peptides and growth factor are released and acts as 
further signals driving regeneration [30]. These are further demonstration of the 
fundamental role of ECM in tissutal homeostasis, a process called “dynamic equilibrium” 
[23].   
When ECM is irreversibly altered by diseases or damage, the equilibrium is lost leading 
to a leak in regenerative and remodelling processes [29].  
Due to its properties in leading and stimulating regeneration, ECM has been investigated 
and applied for therapeutic purposes. ECM scaffolds derived from the porcine small 
intestinal submucosa (SIS), human dermis (Alloderm®) and urinary bladder have been 
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involved in reparation of vessels, skin and lower urinary tract. When applied to damaged 
organs a progressive reabsorption of the scaffold together with a significant tissutal 
regeneration were observed [30, 23, 31]. Skeletal muscle ECM, which is involved in the 
aim of this thesis, has also been investigated in several studies. ECM derived Tibialis 
Anterior of a mouse has been demonstrated to stimulate regeneration when implanted into 
the same muscle which had undergone a wide damage. After 2 weeks from implantation, 
regeneration of myofibers expressing muscle-specific proteins (myosin heavy chain and 
sarcoglycan) was observed. The presence of ongoing regeneration was also demonstrated 
by the presence of abundant cytoplasm and central nuclei in myofibers [32].  
As seen above the structure of ECM is very complex and tissue-specific. The 
reconstruction of artificial ECM starting from single elements would be really difficult. 
For this reason, ECM are usually derived from decellularization processes to be used as 
biologic scaffold in tissue engineering. This way the native ECM and its structure are 
maintained while cellular components responsible of possible rejection are eliminated 
[23, 29, 25].  
 
Tissue engineering of skeletal muscle  
 
Tissue engineering aims to reproduce ex vivo tissues and organs to obtain optimal 
substitute in case of traumatic damages or degenerative diseases. Some clinical 
experiences have already reported with skin, cartilage, vascular grafts, bones and other 
organs [33]. Due to its intrinsic complexity, tissue engineering of skeletal muscle is 
challenging. Several attempts to recreate muscle through artificial scaffold have been 
done. Structures made of matrigel [34], collagen [35, 36], fibrin [37] were created to 
support regeneration and remodelling of myofibers into new functioning contractile 
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muscle. Even if these artificial scaffold acts as a positive support for growth and 
differentiation of muscle precursor cells, the specific three-dimensional architecture and 
arrangement of all types of molecules in ECM has already been described as fundamental 
in determining growth and fate of cells. As seen previously, the whole ECM is, indeed, 
the specific product of cellular components of tissues supporting their phenotype and 
function through special and chemical signalling. For these reasons, the ideal bioscaffold 
for skeletal muscle is decellularized ECM obtained from native tissue of a donor. The 
ideal result should be a three-dimensional structure preserving physical and mechanical 
properties, maintaining tissutal homeostasis and supporting cell-matrix interactions [38]. 
Xenogenic ECM for muscle regeneration have been obtained from porcine small 
intestinal submucosa (SIS) and porcine urinary bladder mucosa (UB). These scaffolds 
have been well characterized [39, 40].  
Porcine SIS is composed primarily by type I collagen, but also elastin and collagen types 
III, IV, and VI. In SIS glycoproteins such as fibronectin and laminin, glycosaminoglycans 
and proteoglycans are present mediating cell adhesion and attachment to the ECM. In 
addition, capability to bind growth factors and to retain enzymes has been observed. SIS 
represent a good biomaterial for muscle tissue engineering, thanks to its size, 
membranous configurations, uniformity, and availability. SIS has been clinically used to 
repair inguinal hernia and large abdominal wall defects, urinary tract, tendons, 
musculotendinous structures, vessels, and dermal wounds [41-46].  
From porcine UB two ECM bioscaffold can be derived: from tunica mucosa including 
basement membrane and from tunica sub mucosa. UB-ECM has been demonstrated to 
retain several growth factors among which VEGF, TGFbeta, PDGF, and basic fibroblast 
growth factor seem to mainly contribute to the regenerative potential of the scaffold. In 
addition to regeneration and healing, UB is characterized by antimicrobial properties [47-
49]. Moreover, a prevalence of M2 macrophages in UB-ECM post-implantation period 
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has been observed and it is relevant to reduce scar deposition and enhance functional 
tissue regeneration [50].  
Differently from SIS and UB, scaffolds derived from skeletal muscle are less 
characterized and they are now involved in some studies. As stated previously, it is 
evident that muscle tissue engineering needs a scaffold preserving composition of three-
dimensional structure in which the correct parallel alignment of myofibers and the 
maintenance of mechanical properties becomes fundamental for function of the 
regenerated tissue. The first of few studies describing muscle-ECM properties is that from 
Perniconi [51]. They demonstrated that the scaffold provides the correct support for 
myofibers development and the appropriate architecture for muscle fiber formation. 
When implanted in vivo, the activation of myogenic process and the formation of new 
myofibers in areas within the bioscaffold were observed even if the grafts had almost 
completely degraded after 4 weeks.  
Other authors demonstrated also that, after decellularization, muscle ECM retains 
collagen and GAGs composition, the overall architecture of the native ECM, same 
mechanical properties, and the capability to sustain myogenic cells [52].   
 
Decellularization of tissues for ECM-scaffold production 
 
As seen in previous chapters the ideal bioscaffold for tissue engineering seems to be the 
native acellular ECM of the organ, especially for skeletal muscle regeneration. To obtain 
ECM, decellularization technique becomes fundamental. Through decellularization a 
complete removal of cells from ECM is obtained while three-dimensional architecture, 
mechanical and chemical properties are preserved [53]. Major histocompatibility 
complexes I and II and nucleic acids of cells are responsible of individual specificity and, 
as consequence, of the probable immune-mediated rejection of a graft. For this reason, 
14 
 
removal of cellular components is important for a correct integration of the scaffold. In 
order to obtain pro-regenerative ECM scaffold, several decellularization techniques have 
been developed depending on the characteristics of the tissue, such as size, cellularity, 
density and thickness [54].  
Treatments can be physical, enzymatic or chemical, or a combination of them. Physical 
methods include mechanical agitation, freeze/thaw, pressure, electroporation and 
sonication. Enzymes usually employed are trypsin, dispase and endo/exonucleases. 
Chemically it is possible to use alkaline/acid or hypotonic/hypertonic solutions, but also 
chelating agents such as ethylene diamine tetraacetic acid (EDTA) or ethylene glycol 
tetraacetic acid (EGTA). Furthermore, several types of detergents can be used, such as 
the non-ionic Triton X-100, the ionic ones sodium dodecyl sulfate, Triton X-200, sodium 
deoxycholate (SDC) or the zwitterionic CHAPS, Sulfobetaine-10 and -16 or tributyl 
phosphate (TBP) [53, 54].  
Tissue and organs can undergo decellularization treatments through the whole organ 
perfusion or the immersion with agitation. Perfusion through vasculature is very efficient 
as it allows a wide delivery of the agents to remove cells and debris. Perfusion can be 
applied to big organs such as heart [55], lungs [56], and liver [57] but it is not suitable for 
little tissues. Portion of skeletal muscle can not be perfused so the immersion in 
decellularizing solutions and gentle agitation is used [52]. Such technique has also been 
used for several others tissues, for example heart valves [58], blood vessels [59], tendons 
[60], trachea [61], oesophagus [62], dermis [63], and urinary bladder [40]. 
Different criteria have been established to asses if the decellularization could be 
considered acceptable: the amount of dsDNA is less than 50 ng per mg of ECM (dry 
weight); there is not visible nuclear material in tissue sections stained with DAPI or 
hematoxylin and eosin (H&E); the remaining DNA fragments have a length less than 200 
bp [54]. Furthermore, the maintenance of three-dimensional ultrastructure, composition, 
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and mechanical properties of ECM should be assessed after decellularization process. 
Scanning electron microscopy or transmission electron microscopy are usually employed 
to investigate the structure, while histological evaluations (H&E, Masson’s Trichrome, 
Elastic Van Gieson, Alcian Blue) and protein quantifications are useful for assessment of 
the composition of ECM, especially of Collagen, elastin and GAG’s. The presence of 
soluble factors such as cytokines, growth and angiogenic factors may be analysed using 
spectrometry. Most used parameters to evaluate mechanical properties are stiffness and 
elastic modulus [54, 64]. 
The conception of a new ECM-derived bioscaffold should pass through the assessment 
and choice of the best decellularization technique and process for that specific tissue. 
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Aim of the study 
In the introduction, an overview on the complex muscle regeneration process has been 
provided underlining the need for a bioscaffold capable to induce the production of 
muscle with normal structure, but also normal functionality. 
My PhD project has been developed at the Regenerative Medicine Lab of the Paediatric 
Institute of Research in Padova (Italy). The project is strictly connected to previous 
studies form this group. In particular, the group had previously developed an ECM 
scaffold of murine diaphragm through a detergent-enzymatic decellularization process. 
Once implanted in vivo in a murine model, scaffold effect for regenerative purposes was 
observed. The results have been published by Piccoli et al. in 2016 [65]. They 
demonstrated for the first time that “orthotopic transplantation of a decellularized 
diaphragmatic muscle from wild animals promoted tissue functional recovery in an 
established atrophic mouse model. In particular, ECM supported a local 
immunoresponse activating a pro-regenerative environment and stimulating host muscle 
progenitor cell activation and migration. These results indicate that acellular scaffolds 
may represent a suitable regenerative medicine option for improving performance of 
diseased muscles”. 
Following these results, further investigations on development of muscular acellular 
ECM scaffold were planned and carried out in this PhD project. 
The aims of the study are: 
- To investigate the efficacy of the same decellularization protocol when applied to 
tissues different from muscle (skin, intestine). Pathologic muscle 
(rhabdomyosarcoma) was also investigated.  
- To investigate the regenerative effect of acellular ECM of different tissues (skin, 
intestine) when applied on diaphragm. Moreover, the macrophagic population 
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(M1 and M2) is investigated to obtain data about immuneresponse elicited by 
these scaffolds. 
- To investigate the regenerative effect of acellular ECM derived from muscle and 
different tissues (skin, intestine, rabdomiosarcoma) in a murine model of Volume 
Muscle Loss. 
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Materials and methods  
Animals 
All surgical procedures and animal husbandry were carried out in accordance with 
University of Padua's Animal care and the Ministry of Health (protocol number 862/2016-
PR and 304/2017) in accordance with the Italian Law on the use of experimental animals 
(DL n. 16/92 art. 5). The animals used as donors (quadriceps, skin, intestine for scaffold 
generation) were 12 week-old wild type C57BL/6j male and female; 12 week-old 
C57BL/6j mice were used also as recipients. 
For xenogenic Alveolar Rhabdomyosarcoma production,  
Balb\c Rag2-/- gamma c-/- mice from Jackson laboratories were used to grow xenograft of 
alveolar rhabdomyosarcoma tumors after injection in flanks of RH30 cell line. Mice were 
12 week-old, male and female. 
 
Tissues decellularization 
The decellularization was obtained using a detergent enzymatic treatment (DET) [65], in 
which both chemical agents and enzymes were employed. Specifically, 4% SDC (Sigma-
Aldrich) was used as detergent and deoxyribonuclease I (DNaseI) (Sigma-Aldrich) as 
enzyme. Quadriceps muscles, skin and intestine samples were cut in half and then washed 
in sterile 1X PBS. A DET cycle consists of 3 passages. First, the quadriceps were 
maintained in 40 mL of sterile and deionized water at 4° C for 24 hours. Then, the samples 
were put in 40 mL of 4% SDC for 4 hours at RT and in gentle agitation. After that, 
samples were washed 3 or 4 times with sterile and deionized water, to remove the 
detergent that could inhibit the DNase I (or could be toxic for cells if the scaffold will be 
recellularized or implanted in vivo). At last, the tissues were put in 40 mL of 2000 kU 
DNaseI (Sigma-Aldrich) in 1 M NaCl (Sigma-Aldrich) for 3 hours at RT and in gentle 
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agitation. Then, another cycle started. After decellularization, matrices were rinsed for at 
least 3 days in 1X PBS with 3% P/S (Gibco-Life Technologies), immediately analyzed 
or stored in freezing medium composed of 70% FBS, 20% DMSO, 10% DMEM high 
glucose and frozen in liquid nitrogen.  
Rhabdomyosarcoma decellularization. The detergent used was 1% SDS (Sigma-
Aldrich)and the procedure was the same as described above. 
 
DNA extraction 
To assess total DNA content within the native fresh and decellularized tissues, specimens 
were treated using DNeasy for blood & tissues (Qiagen). Samples (up to 25 mg tissue) 
were first lysed overnight using proteinase K and buffer ATL. After lysis, 200 μL of 
absolute ethanol were added to provide optimal DNA binding conditions and the lysate 
was loaded onto the DNeasy Mini spin column. During centrifugation at 8000 rpm for 1 
minute, DNA is selectively bound to the DNeasy membrane as contaminants pass 
through. Remaining contaminants and enzyme inhibitors are removed by washing with 
buffers AW1 and AW2. After the addition of each buffer, tubes were centrifuged at 14000 
rpm for 3 minutes. DNA was then prepared for elution by adding buffer AE, left to act 
for 1 minute. Columns were then centrifuged at 8000 rpm for 1 minute in a new tube, in 
which nucleic acids were eluted. 
 
DNA quantification 
DNA extracts were evaluated using Nanodrop 2000 (Thermo scientific, USA). Nucleic 
acids have an absorption maximum at 260 nm. Most samples contain contaminates such 
as proteins and single stranded DNA/RNA that absorb maximally at 280 nm. Hence, 
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optical densities at 260 nm and 280 nm were used to estimate the purity and yield of 
nucleic acids, which were quantified on the basis of 260 nm absorbance. 
 
DNA gel electrophoresis 
To verify whether the DNA found in extracts from tissues after each DET cycle was 
genomic or only composed by fragments retained in the matrix, a gel electrophoresis was 
performed. 33 μL out of 100 μL of DNA extracted from samples were took and 
resuspended with 8.25 μL of loading buffer. 20 μL of each sample was loaded in a 0.8% 
Agarose in TBE 1X gel, in which we added 8 μL of SybrSafe, a reagent that binds to 
DNA and allows its visualization when exposed to UV light. Gel electrophoresis run was 
done at 110 V for 90 minutes. 
 
ECM component quantification 
Collagen quantification 
The collagen content of fresh and decellularized tissues was quantified using the SIRCOL 
collagen assay (Biocolor, UK) according to the manufacturer’s instructions. The samples 
were incubated over night at 4° C with 1 mL of 0.5 M acetic acid containing 0.1 mg of 
pepsin, to remove the terminal non-helical telopeptides and release the collagen into 
solution. Extracts were then incubated overnight at 4° C with Acid Neutralising Reagent 
(contains TRIS-HCl and NaOH) and Collagen Isolation & Concentration Reagent 
(contains polyethylene glycol in a TRIS-HCl buffer, pH 7.6). After this step, samples 
were centrifuged at 12000 rpm for 10 minutes, supernatant was removed, and samples 
were incubated 30 minutes in a mechanical shaker with Sirius red dye. Samples were 
centrifuged again at 12000 rpm for 10 minutes, supernatant was removed and Acid-Salt 
Wash Reagent (containing acetic acid, sodium chloride and surfactants) was added to 
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remove unbound dye from the surface of the pellet and the inside surface of the micro-
centrifuge tube. A final centrifugation step at 12000 rpm for 10 minutes was done and 
supernatant was removed. Alkali reagent (contains 0.5 M sodium hydroxide) was added 
and tubes were vortexed to release Sircol dye from the collagen-dye complex. A volume 
of 200 μL of each sample was transferred into a 96 well microplate and Absorbance was 
determined at 555 nm with a microplate reader (Biorad). Reading was made at this 
absorbance because the spectrum chart of the Sircol Dye in Alkali Reagent has a peak 
maximum in the visible region of 555 nm. Aliquots containing 50, 25, 12.5, 6.25 and 0 
μg of the Collagen Reference Standard (made of Collagen I extracted from bovine skin) 
were used to create a standard curve with which it was possible to calculate the collagen 
content of the different fresh or decellularized samples. 
 
Glycosaminoglycans quantification 
The sulfated glycosaminoglycans (sGAG) content of fresh and decellularized tissues was 
quantified using the Blyscan GAG Assay Kit (Biocolor, UK). 50 mg of wet fresh or 
decellularized tissue were weighed and placed in a microcentrifuge tube containing 1 mL 
of Papain Extraction Reagent: 0.2 M sodium phosphate buffer (Na2HPO4 – NaH2PO4) at 
pH 6.4, 0.1 M sodium acetate, 0.01 MNa2EDTA, 0.005 M cysteine HCl, 15-20 mg of 
papain, and incubated in a water bath at 65° C for 3 hours. Samples were then centrifuged 
at 10000 rpm for 10 minutes and supernatant was decanted off. Each sample was 
incubated for 30 minutes in a mechanical shaker with Blyscan dye (contains 1,9-
dimethylmethylene). Samples were centrifuged at 12000 rpm for 10 minutes, surnatant 
was carefully removed and dissociation reagent was added (contains the sodium salt of 
an anionic surfactant) to dissociate the sGAG-dye complex and enhance the 
spectrophotometric absorption profile of the free dye. A volume of 200 μL of each sample 
was transferred into a 96 well microplate and Absorbance at 656 nm was measured using 
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a microplate reader (Biorad). Reading was made at this absorbance because the spectrum 
of the Blyscan Dyein the Dissociation Reagent has a peak maximum of 656 nm. A 
standard curve was set up using GAG standards containing 1, 2, 3, 4 and 5 μg of bovine 
trachealchondroitin-4-sulfate, to determine the GAG content. 
 
Freezing process 
All the tissue samples were fixed with 4% PFA for 1 hour at 4° C. Then, they were 
dehydrated with a sucrose gradient (10%, 15% and 30%) (Fluka), in order to maintain the 
original structure of the tissue. At last, they were included in the cryostat embedding 
medium O.C.T. (Kaltek) and frozen in liquid nitrogen using isopentane (Sigma-Aldrich). 
The frozen tissues were sectioned with cryostat (Leica CM1520) in sheets of 6-7 m. 
 
Microscopes and imaging system 
Phase-contrast images were collected using an inverted microscope (Olympus IX71). 
Immunofluorescence analyses were performed using a fluorescence inverted microscope 
(Leica B5000). 
 
Immunofluorescence 
Tissue slides (both from the in vivo and in vitro experiments) were permealized with 0.5% 
Triton X-100 in 1X PBS for 10 minutes at RT. After, the samples were rinsed in 1X PBS 
for 5 minutes and then saturated with 5% HS in 1X PBS for 12 minutes and with mouse 
serum in 1X PBS (dilution 1:10, Sigma-Aldrich) for 30 minutes at RT. Another washing 
step in 1X PBS for 5 minutes was done. Sample were then incubated with primary 
antibody for 1 hour at 37° C or over night at 4° C. After a washing step with 1X PBS, 
they were incubated with labeled secondary antibody for 1 hour at 37° C. After the last 
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washing step with 1X PBS, nuclei were counter stained with fluorescent mounting 
medium plus 100 ng/mL 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich).  
Antibodies used for immunofluorescence are summarized in table 1. 
 
Primary Antibodies Manufacturer Dilution 
rabbit anti-mouse Myf5 Santa Cruz 1:80 
rabbit anti-mouse Ki67 Abcam 1:100 
rabbit anti-mouse Laminin Sigma-Aldrich 1:200 
rat anti-mouse Laminin Santa Cruz 1:80, with over night 
incubation 
mouse anti-human PAX7 R&D Systems 1:50 
mouse anti-human Lamin A/C Leica 1:100 
rabbit anti-mouse Collagen type 1 Thermo Scientific 1:80 
rabbit anti-human Cleaved 
Caspase-3 
Cell signalling 1:300, with overnight 
incubation 
mouse anti-human MyoD Dako 1:80, with overnight 
incubation 
mouse anti-mouse MYH3 Santa Cruz 1:100 
rabbit anti-human Myogenin Santa Cruz 1:100, with overnight 
incubation 
   
Secondary Antibodies   
Alexa Fluor chicken anti-rabbit 
594 
Life Technologies 1:200 
Alexa Fluor chicken anti-rabbit 
488 
Life Technologies 1:200 
Alexa Fluor goat anti-mouse 594 Life Technologies 1:200 
Alexa Fluor goat anti-rat 568 Life Technologies 1:200 
Alexa Fluor goat anti-rat 488 Life Technologies 1:200 
Tab 1: List of antibodies used for Immunofluorescence. 
 
 
Histology 
Frozen sections (6-7m thick) were stained with H&E kit for rapid frozen section, Alcian 
Blue, and with Masson's Trichrome (MT) with aniline blue kit (all from Bio-Optica, UK) 
under manufacturer's instruction. 
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In vivo implantation 
Orthotropic implantation on diaphragm 
Surgical procedure was carried as previously described. Briefly, while in a recumbent 
position, a medial incision was performed in the abdomen of the mouse. To visualize the 
diaphragm, liver and stomach were then gently moved aside with the help of a sterile 
gauze. Patches of skin and intestine (0,7x0,7 cm each) were fixed on the left side of the 
native diaphragm with stitches of Prolene 8/0. Organs were then repositioned into the 
abdominal cavity. The abdominal wall was closed in two layers and the animals were left 
to wake up under a heating lamp. Mice were euthanized by cervical dislocation at 7 and 
15 days post implantation. 
 
Implantation on tibialis anterioris muscle (VML model) 
C57BL/6j mice were used when surgical application of natural- derived scaffolds was 
performed. Surgery was performed in order to create a standardized murine model of TA 
VML injury for the application of biocompatible scaffolds (Fig 4). Mouse were gently 
handled in general anesthesia with O2 and isofluorane (Forane, Merial, IT). The mid-belly 
region of TA muscle was visualized through a 0.5-1 cm incision longitudinally in the 
epidermis, dermis, and fascia. A 4 x 4 x 3 mm thickness segment was resected from 
muscle mass, and an average defect muscle mass of 25-30 mg was excised [66]. Defects 
were treated with size-matched biocompatible scaffolds: 
1. Decellularized healthy quadriceps 
2. Intestine decellularized extracellular matrix 
3. Skin decellularized extracellular matrix 
4. Alveolar rhabdomyosarcoma decellularized extracellular matrix 
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The scaffolds were hydrated using normal saline buffer before dermal closure with 7-0 
prolene. The deep fascia and skin were closed using non-absorbable sutures [67]. 
Afterwards, the animals were checked to ensure arousal within 10 minutes after surgery 
and moved back to their cages monitored for activity, ability to drink and eat and for signs 
of bleeding or infection. Analgesics (as painkillers), antibiotics and saline solution (for 
rehydration) were administered. All animals survived the surgical procedure and study 
period without complications. Mice were euthanized by cervical dislocation at 7 and 15 
days post implantation. List of treated animals is provided in table 2. 
 
Natural-derived 
Scaffolds have been previously prepared, cut in 4 x 3 x 3 mm size using a biopsy punch 
of 5 mm, washed and weighed. 
 
Figure 4: Surgical procedure for VML defect in TA muscle of a murine model (Fig. XXX): A) Middle 
incision and muscle resection to create the VML into the TA muscle. B) Application of biocompatible 
scaffolds. C) Closure of the treated TA muscle and skin.  
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Tab. 2: Weight of the muscle surgical resections and subsequent implanted scaffolds. 
Legend QUADRICEP INTESTINE SKIN ARMS
# mouse
Surgical resection (mg) Weight  of the scaffold (mg) Surgical resection (mg) Weight  of the scaffold  (mg)
1 30,5 38
2 19 33
3 18,5 30
4 29,8 36
5 21,4 30
6 29,1 32
7 23 35 25 39
8 33,3 34,5 22,7 35,8
9 22,8 38 22,1 32,5
10 29 38,8 22,5 32,3
11 17,2 31,9 20,7 30,6
12 29,6 34,5 29,8 36
13 22,2 33 20 32
14 20 31 16 30,9
15 23,8 35 24,6 39
16 21,7 35,5 20 37,5
17 25,1 24 23,9 30
18 24,3 24,7 16,8 29,9
19 21,7 28,9 19,8 31,2
20 22,2 26,5 19,8 30,2
21 28 24,2 32,2 31,7
22 30,2 29 26,5 33,2
23 18,6 32,1 21,1 27,5
24 24,9 31 30,7 33,1
25 13,8 33 19,7 29,4
26 19,8 24 17,3 31,5
27 20,4 28,7 15,6 23,3
28 14,7 23 18 21,3
29 19,9 22,5 16,5 26,7
30 29,4 34,1 21 27,1
31 26,5 29,5 24,8 28,4
32 24,2 24,6 18,6 26,7
33 24,9 34,3 18,7 34,3
34 25,9 32,2 25,8 32,6
35 18,8 34,8 23,3 35,3
36 24,9 34 28,8 34,2
37 21,9 34,1 34,6 36,8
38 19,6 33,7 28,7 35,1
39 21,5 35,6 18,7 34,3
40 12,3 35,6 23,3 34,2
41 25,8 37,2 18 33,3
42 18,8 23 16,2 27,1
43 16,6 34,7 18,9 34,1
44 25 24,1 23,6 26,3
45 27,5 24,1 31 25,5
46 20,5 26,5 20,6 23,2
47 28,8 21 25,9 18,5
48 19,7 26 19,5 21
49 21,1 27,5 20,8 25,8
50 19,4 25 18 25,3
51 17,8 25,3 16,4 24,6
52 18,4 22,4 15,7 21,9
53 17,7 25,7 14,4 24,2
54 17,5 22,8 19,6 23,3
55 16,1 20,7 16,1 24,4
Avarage 22,5 29,9 21,7 29,8
Tibialis Anterioris Left Tibialis Anterioris Right
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RNA extraction and RealTime PCR analyses    
The RNA was extracted from TA, treated with quadriceps, intestine, skin and ARMS, at 
two time points (7 and 15 days). Samples were collected in 1 mL of Trizol and 
mechanically homogenized using Tissue Lyser (Qiagen), then 200 L of chloroform 
were added and the samples were mixed for 15 seconds. After 5 minutes at RT they were 
centrifuged at 4° C for 15 minutes at 13000 g in order to separate the aqueous phase from 
the organic one. From the aqueous phase the RNA was extracted with the RNeasy® Plus 
Mini Kit (QIAGEN®) and then quantified with a ND-2000 spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). One µg of RNA was reverse transcripted using High 
Capacity Reverse Transcription kit (Applied Biosystems) following manifacturer’s 
instructions.  
Afterwards, RealTime PCR reactions were performed in order to analyze the expression 
of Nos2, Arg1, Myog and Myh3. Ribosomal RNA 18S was used as housekeeping gene. 
Table 3 shows the primer sequences, the annealing temperature and the length of the 
product for each gene. 
RealTime PCR reactions were performed using a LightCycler II (Roche, Monza, Italy). 
Reactions were carried out in triplicate using 4 µL of FASTSTART SYBR GREEN 
MASTER (Roche) and 2 µL of primers mix FW + REV (final concentration, 300/300 
nM) in a final volume of 20 µL. Serial dilutions of a positive control sample were used 
to create a standard curve for the relative quantification. The amount of each mRNA was 
normalized over the expression of 18S.  
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Gene Primers 
T 
(°C) 
Product 
length (bp) 
Nos2 
FW: GCAGGTCTTTGACGCTCGGA 
RV: ATGGCCGACCTGATGTTGCC 
60 105 
Arg1 
FW: AGACCACAGTCTGGCAGTTGG 
RV: AGGTTGCCCATGCAGATTCCC 
60 136 
Myog 
FW: GCAATGCACTGGAGTTCG 
RV: ACGATGGACGTAAGGGAGTG  
58 94 
Myh3 
FW: AGGCCTTGTGCTTTCCCAGAG 
RV: GTTCACAGCATGGTGAACCTGG 
 
60 
86 
18S 
FW: CAACTTCAATGTCGGATGGATG 
RV: GCTGTGCTCGCGCTACTCT 
 
60 
161 
Table 3: RealTime PCR. Primers, annealing temperatures and length products of the 
cDNA amplified with the PCR. FW: forward; RV: reverse. 
 
Statistical analyses 
Statistical analyses were performed with GraphPad Prism software 5. The data are 
presented as the mean ± S.E.M. Differences between data groups were evaluated for 
significance using the unpaired Student's t-test. P-values indicated on figures are * = p < 
.05; ** = p < .01; *** = p < .001. 
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Results 
Analysis of decellularized scaffolds 
In Fig. 5 and 6 structure and composition of decellularized skin and intestine are reported. 
After 3 Detergent-Enzymatic treatment cycles comparable results were observed for 
intestine and skin. Immunofluorescence for DAPI (cells nuclei) and laminin (ECM 
component surrounding cells) demonstrated that after 3 detergent enzymatic cycles the 
structure of cells remained but no nuclei were still visible. DNA quantification together 
with electrophoresis confirmed the significative absence of cellular remnants in the 
samples.  
Histologic staining and quantification assay showed a substantial stability in collagen and 
GAGs distribution and quantity. After 3 cycles of Detergent-Enzymatic treatment the 
extracellular matrix structure and composition of skin and intestine was not significantly 
altered while a successful decellularization was achieved.  
Qaudricep and ARMS scaffold obtained with the same decellularization protocol, have 
been investigated by authors of the same laboratory. Results demonstrated that also ECM 
scaffold from these tissues retains structural properties comparable to those of the fresh 
tissue. Results have been recently published by the authors [80, 81] and they are reported 
in Fig. 7, 8, and 9. 
In particular for ARMS ECM the new detergent SDS instead of SCD was used to rich to 
decellularization efficiency. 
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Fig. 5. Characterization of Skin ECM after decellularization. Results after 3 DET cycles. 
Immunofluorescence (A), Nuclei quantification (B), DNA quantification (C), and ECM Components 
(D) are reported. 
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Fig. 6. Characterization of Intestine ECM after decellularization. Results after 3 DET cycles. 
Immunofluorescence (A), Nuclei quantification (B), DNA quantification (C), and ECM Components 
(D) are reported. 
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Fig. 7. Results of characterization of ARMS scaffold. Decellularization protocol and efﬁciency of the 
procedure. (a) Different phases of the protocol. Gross appearance of fresh and decellularized sample. 
DNA quantiﬁcation and agarose gel. (b) Upper row: Hematox- ylin Eosin; lower row: Alcian blue 
(AB) at different cycles. Nuclei are depleted but tissue shape is maintained at different cycles. Scale 
bar: 50 μm ****p<0.0001. From Pozzobon et al. Alveolar Rhabdomyosarcoma Decellularization. 
Methods Mol Biol. 2017 May 25. 
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Fig. 8. Decellularization efﬁciency for quadricep scaffold. (a) Representative images of fresh and 
decellularized samples. (b) DNA amount quantiﬁcation. (c) Quantiﬁcation of the number of nuclei per 
ﬁeld. (d) Evaluation of cross sectional area (CSA) of muscle ﬁbers. (e) Quantiﬁcation of the number 
of ﬁbers per ﬁeld. * p < .05; ** p < .01; *** p < .001. From Piccoli et al. Mouse Skeletal Muscle 
Decellularization. Methods Mol Biol. 2017 Apr 28. 
 
 
Fig. 9. Extracellular quadricep matrix (ECM) preservation. (a) Representative images of Hematoxylin 
& Eosin (H&E) stain on fresh and decellularized samples. (b) Scanning electron microscopy (SEM) 
images of fresh and decellular- ized quadriceps. (c) Quantiﬁcation of collagen on muscle samples. (d) 
Quantiﬁcation of sulphated glycosami- noglycan (sGAG) of fresh and decellularized muscles. * p < 
.05. From Piccoli et al. Mouse Skeletal Muscle Decellularization. Methods Mol Biol. 2017 Apr 28. 
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Results of in vivo application 
Skin and intestine ECM implanted in diaphragm. 
Immunofluorescence and histological analysis  
Immunofluorescence examination of skin and intestine scaffold implanted on diaphragm 
showed that a migration of cells from the host inside the scaffold is present. Indeed, in 
both cases positivity for nuclear staining (DAPI) was detected at 7 and 15 days after 
implantation.  
Histologic measurement performed on these samples showed signs of remodelling of the 
native diaphragm. Remodelling is represented by a significant increase in thickness of 
native diaphragm, number of myofibers and of their cross-sectional area. All these effects 
were progressively increasing through the analysed time points. Moreover, scaffolds were 
progressively reabsorbed after implantation (Fig. 10 and 11) 
 
 
Fig. 10. Immunofluorescence (A) and histologic measurements (B) after implantation of skin scaffolds 
on diaphragm. 
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Fig. 11. Immunofluorescence (A) and histologic measurements (B) after implantation of intestine 
scaffolds on diaphragm. 
 
Volume muscle loss model. 
Histological analysis  
Figure 12 and 13 shows histologic findings at 7 and 15 days after scaffolds implantation 
on tibialis anterior. Staining for H&E and Masson’s Trichromic (MT) are reported as 
morphologic results. 
At 7 days quadricep scaffold stimulates a reparative reorganization of muscular fibers. 
Indeed, confines of the damage are characterized by regularly oriented cells towards a 
reparative process. MT staining shows a difference in collagen quantity between the 
native muscle and the scaffold, but a migration of muscle cells inside the latter is already 
detectable. Skin, intestine and ARMS scaffold applied on muscle did not show muscle 
fibers regeneration at the edge of the damage neither an architectural pattern similar to 
muscle. ARMS scaffold is the most similar to the quadriceps one but no regeneration is 
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induced after its implantation. MT staining unveils a sharp separation between the skin 
scaffold and the muscle as a result of lack in integration. Moreover, MT staining 
underlines that no muscle cells are shown to be present inside the scaffold derived from 
skin, intestine and ARMS. 
At 15 days after implantation of quadricep scaffold, regeneration and repair of muscle 
improved. A regularly organized structure and real myofibers are visible in the area of 
the scaffold and along the damage line. Histology of quadricep implants showed also the 
presence of new blood vessels inside the scaffold supporting the regenerative process. On 
contrary, skin and intestine implantation resulted in a completely disarranged structure of 
the muscle suggesting that no reparative nor regenerative processes are present. On MT 
staining it is also evident how these scaffolds are progressively reabsorbed. ARMS 
scaffold implantation at 15 days shows a diffuse infiltration of lymphocytes and 
monocytes suggesting an immunological response by the host. Even if this kind of 
response is fundamental in reparative process, no signs of regenerated muscle is visible 
15 days after implantation of ARMS. 
 
Fig. 12. Histological findings at 7 days after implantation in a VML model. 
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Fig. 13. Histological findings at 15 days after implantation in a VML model. 
 
Immunofluorescence and qRT-PCR  
Figures 14 and 15 shows results of immunofluorescence in VML model. 
Immunofluorescence stainings were focused on macrophagic response (CD68) and new 
myofibers formation (Myogenin). As seen above, macrophages are fundamental in 
reparative and regenerative processes. Stainings for DAPI and laminin are also present to 
detect nuclei and muscular cells. 
At 7 days after implantation macrophages surround the quadricep scaffold where new 
small centre-nucleated myofibers are also visible (Laminin+, DAPI+, Myogenin+). Skin 
and intestine scaffold are surrounded by macrophages demonstrating the activity of 
immune response but no regenerated myofibers are detectable. ARMS evokes a 
macrophagic response and small myofibers are visible but no central nuclei are visible 
suggesting an anomalous cellular regeneration. 
Myogenin staining is specific for newly regenerated myofibers and it is detectable only 
in quadricep samples.  
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At 7 days post ECM implant Myogenin is detectable only in quadriceps treated mice, 
demonstrating the complete maturation of myofibers. In this group, an organized structure 
and disposition of myofibers is visible. At the later time point, 15 days, in all treated group 
Myogenin is absent.  
In ARMS repaired muscle, scattered small myofibers are visible but they are not 
organized into a normal muscular architecture. In skin and intestine repaired muscle no 
regenerated myofibers are present in the damage area. CD68 staining shows that 
macrophages are still active at 15 days after implantation but with different patterns. In 
quadricep treated mice macrophages distribution is uniform around the contact area 
between the scaffold and the native muscle, while in the other treated mice their presence 
is weaker and more scattered. 
 
 
Fig. 14. Immunofluorescence study at 7 days after implantation in VML model. DAPI (blue), Laminin 
(green), CD68 and Myogenin (red in corresponding rows). 
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Fig. 15. Immunofluorescence study at 15 days after implantation in VML model. DAPI (blue), 
Laminin (green), CD68 and Myogenin (red in corresponding rows). 
 
In parallel to the staining against the pan macrophages CD68, we performed gene 
expression for the macrophages polarized toward M1 (iNOS2) – involved in 
inflammation - and M2 (Arginase I) – involved in regeneration process. As shown in 
figure 16, at 7 and 15 days the damage alters the homeostasis of the muscle, but we did 
not detect significative pro regenerative response with none of the implanted ECM. It will 
be important to consider earlier and later time points to evaluate better the role of both 
M1 and M2 as inflammatory and regenerative macrophages respectively. We also 
analysed the gene expression of the embryonic myosin heavy chain (MHC3) and 
Myogenin, usually present during the early phases of myofiber regeneration. It was 
evident how the damage stimulated these genes but none of the implanted ECM really 
enhanced them, for the analysed time points.  
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Fig. 16. Real time PCR. Data at 7 and 15 days post-implantation are shown for each scaffold. 
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Discussion 
The treatment of diseases related to muscular defects represents a challenge for clinicians. 
In this study models of congenital diaphragmatic hernia (CDH) and volume muscle loss 
(VML) have been proposed. These models stand for two different origin of muscular 
defect, the first due to congenital malformation and the second to traumatic or surgical 
ablation.  
CDH is a rare and severe condition in which abdominal organs herniate in the thorax 
through a diaphragmatic defect in association to a significant lung hypoplasia. Treatment 
is based on intensive care resuscitation at birth and then surgical repair of the defect. 
Despite all the efforts to improve survival in CDH, mortality remains high [68]. When 
feasible, repair can be led through primary suture of the defect or by interposition of a 
prosthetic patch. Materials used for patches are usually artificial and connected to several 
complications and comorbidities, also with long-term onset. Infection, hernia recurrence, 
scoliosis, hernia recurrence, gastro-oesophageal reflux, and thorax deformities are the 
most cited complications related to use of synthetic patches [69].  
VML typically results from traumatic incidents or surgical resections mainly due to 
tumors or infections. These injuries may lead to extensive loss of muscle and of its 
basement membrane significantly compromising functionality and quality of life of 
patients [70]. While skeletal muscle has innate capability to repair limited injuries, this 
does not happen with large-scale lesions. This is maybe related to the loss of muscle 
template and growth factor reservoir. Nowadays VML injuries are treated by 
transposition on skeletal muscle from a donor site of the same patient. This procedure has 
limited results in terms of functionality and it is affected by several complications such 
as infection and graft failure with necrosis [71]. 
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In both cases of malformed or injured muscle, it is of primary relevance to obtain a 
bioscaffold suitable for muscle repairing and regeneration. Properties of the ideal 
bioscaffold are support to cell alignment, promotion of muscle formation in association 
with development of vascularization and innervation. Extracellular matrix (ECM) is 
nowadays investigated potentially as the ideal platform for a muscular scaffold. ECM, 
indeed, preserves the complex ultrastructure surrounding and supporting cells. Moreover, 
it retains angiogenic and growth factors that are fundamental in chemotactic process of 
tissutal regeneration.  
This study is a continuation of a wider project aiming to investigate and produce a muscle 
ECM derived scaffold. Previous study from our group on diaphragmatic scaffold 
production and characterization has been published [65]. Using the same decellularization 
protocol of the present study, they obtained murine diaphragmatic ECM scaffold 
preserving most of the ultrastructural, physic-mechanical, and molecular properties of the 
fresh tissue. They applied the diaphragmatic scaffold on diaphragm of healthy and 
dystrophic mice demonstrating that a pro-regenerative environment and remodelling were 
elicited. Host diaphragm in contact with the scaffold, indeed, showed increase in 
thickness due to formation of real new generated myofibers and not to a foreign body 
reaction-like increase of cross sectional area. The environment, demonstrated to be 
stimulated towards regeneration as the observed switch between macrophagic M1 and 
M2 subtype was observed. No immunoresponse toward rejection was evident. 
In the present study we wanted to explore the efficacy of the detergent-enzymatic protocol 
applied for different tissues. Moreover, using scaffolds derived from different tissues, we 
investigated the role of tissue specificity of the scaffold in relation to regenerative 
potential.  
Detergent Enzymatic decellularization protocol was based on association of Sodium 
Deoxycholate (for skin, intestine and quadriceps), Sodium dodecyl sulphate (for 
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rhabdomyosarcoma) [80] and DNAasi I [72]. Nuclear and DNA depletion is fundamental 
to avoid immune-related rejection of the scaffold as it leads to the removal of MHC-I and 
MHC-II antigens [74]. At the same time residual extracellular matrix maintains same 
ultrastructural and composition characteristics. Ultrastructural and chemotactic properties 
retained in the ECM are fundamental in driving cell migration, differentiation and 
maturation in a pro-regenerative process. With skin, intestine and ARMS we observed 
decellularization results comparable to that obtained in diaphragmatic tissue. Residing on 
these observations we can speculate that the abnormal muscle regeneration elicited by 
those scaffold is not related to alteration of ECM but to the intrinsic characteristics of the 
matrix itself.  
In vivo application of skin and intestine on diaphragm resulted in anomalous remodelling 
of native muscle. Even if a migration of cells inside the scaffold was observed, no 
regeneration of muscle was evident. Indeed, increase in thickness of native diaphragm 
corresponded to a parallel increase in cross sectional area of myofibers. This reaction 
could be related to an inflammatory response towards a foreign body leading to 
hypertrophy of the native tissue surrounding the scaffold. This was not observed by 
Piccoli et al with diaphragmatic scaffold implantation as signs of newly regenerated 
myofibers were evident: increasing thickness corresponded to a more significant increase 
in number of centre nucleated myofibers without cross sectional area augmentation. Also 
scaffold derived from intestine and skin showed a progressive reabsorbance confirming 
the degradation fate that classically distinguishes biological scaffolds [73]. 
In order to investigate a model of volume muscle loss injury, experiments on tibialis 
anterioris muscle was conducted. In this part of the experiment we wanted to compare 
skeletal muscle scaffold to other derived from different tissues. Implantation of quadricep 
scaffold elicited damage repair through regeneration of new myofibers. In the contact 
area between scaffold and muscle, indeed, new centre-nucleated myofibers are visible 
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arranging into parallel disposition typical of muscular tissue. Moreover, examining 
myogenin staining, marker expressed during the first stages of myogenesis that is 
switched off when myofibers are completely formed, we demonstrated that only in 
quadriceps visible myofibers are really newly regenerated. The implantation of scaffold 
derived from skin and intestine did not show any stimulus toward regeneration. New 
myofibers or muscle-like cells were not observed in the area of the scaffold while a re-
arrangement of native muscle was evoked as a sign of reparation and reaction for tissue 
remodelling. Differences in regenerative efficacy may reside in the origin of the scaffold 
and this is a further demonstration that different 3D architecture and composition of the 
ECM give not the correct signalling and stimulus towards correct regeneration. Indeed, 
ECM is capable to stimulate recruitment and proliferation of appropriate cell types 
involved in the regeneration process [75].  
In this study we wanted also to test ECM derived from pathologic muscle. The aim was 
to investigate not only the effect of the biochemical factors present in pathological ECM 
but also the action of a disorganized pathological ECM muscle derived. We decided to 
use ECM derived from rabdomyosarcoma (ARMS). Implantation of ARMS elicited the 
formation of myofibers inside the scaffold area but they arranged into a not organized 
muscular pattern. Moreover, such generated myofibers appeared scattered, small and not 
centre-nucleated giving the suspicion that they may not be adequate for a real muscle 
regeneration. These observations on ARMS scaffold indicate that illness alters also 
composition and properties of tissue even if the origin is the same.  
Gene expression for embryonic myosin heavy chain and myogenin after 7 and 15 days 
did not show a specific enhancement, further analysis of both gene for early and later time 
point are planned.  
Angiogenic properties are fundamental in tissue engineering of muscle. Blood perfusion 
allows a tissue to be maintained and delivers cells and factors necessary to complete 
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regeneration. ECM usually possess angiogenic properties attracting endothelial cells to 
repopulate vessels structures in the matrix [76]. Consistently with other studies [74], in 
our study blood vessels were observed inside the muscle scaffold near the interface with 
damaged muscle. Interesting was that with implantation of different scaffold no signs of 
revascularization were visible. This difference may be of primary importance to delineate 
the basis for a bioscaffold-based regeneration. Generally, ECM retains angiogenic soluble 
factors (such as VEGF) [23] but mismatch in the structure of the tissue may affect also 
the revascularization process. 
In VML part of the study a focus on macrophagic response has also been provided. It is 
known that macrophages can have different phenotypes modulated by soluble factors [77, 
78] and that can influence the environment towards regeneration (M2 type) or perpetual 
inflammation (M1 type) [79]. In our experiment, macrophagic presence could be 
observed after implantation of all the scaffolds and also gene expression for M1 and M2 
highlighted this homogeneous behaviour. Only after implantation of quadricep ECM, new 
regenerated fibers were observed and we could postulate that also macrophages play a 
regenerative role. The other scaffolds did not show the same newly born fibers and this 
may reside in the anomalous implanted ECM structure that did not drove adequate 
regenerative signalling from the microenvironment and from the macrophages.  
Results obtained with rtPCR analysis did not provide significant results in terms of 
regeneration of new myofibers and antiflogistic (proregenerative) environment. We 
consider that investigations on earlier and later time points may reveal a deeper 
characterization on these aspects.  
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Conclusions 
This study is a part of a wider project aiming to create a valid substitute for skeletal muscle 
based on bioscaffold derived from extracellular matrix. This kind of bioscaffold seems to 
be the most reliable in terms of immunoresponse and pro-regenerative properties. 
In this study the tissue-specificity resulted as a fundamental aspect to obtain the best 
response from the scaffold. A tissue specific bioscaffold for muscle carries all the 
structural, chemotactic, pro-angiogenic, and immune-modulating requisites in order to 
obtain a real regeneration of a functional skeletal muscle. The involvement of ECM-based 
scaffold derived from different tissue may lead to a perpetual foreign body-like response 
compromising the deposition of muscular tissue.  
Investigations on rhabdomyosarcoma allowed to confirm that in diseased tissue and 
organs extracellular matrix is affected with significative alteration of its properties. 
Many investigations on muscle ECM-derived bioscaffold are still needed before a clinical 
trial can be set. Deep investigations on angiogenic properties of the scaffold are 
undergoing to reveal another fundamental side of regenerative potential of extracellular 
matrix.  
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